A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Phase 1
Recruiting
- Conditions
- Ovarian CancerEndometrial CancerSoft Tissue SarcomaTriple Negative Breast CancerPancreas CancerSolid TumorsColorectal CancerNeoplasmsBreast CancerColon Cancer
- Interventions
- Drug: LY2880070Drug: Gemcitabine
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Esperas Pharma Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT02632448
- Locations
- π¨π¦
University Health Network - Princess Margaret Hospital, Toronto, Ontario, Canada
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
π¨π¦Cross Cancer Institute, Edmonton, Alberta, Canada
Β© Copyright 2025. All Rights Reserved by MedPath